Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Immunosuppressive Therapy

    ... the U.S. Food and Drug Administration in 2014 to treat refractory aplastic anemia . In 2018, Eltrombopag was FDA approved ...

    Topic section last updated 07/06/2018 - 11:17am.

  2. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant

    ... lacking suitable identical donors and those who are refractory to immunosuppressive therapy (IST). The current study evaluated ...

    Research Article last updated 02/03/2017 - 9:40am.

  3. Patient Trusts Her Instincts in Finding the Right Treatment

    ... MDS (myelodysplastic syndrome). Specifically, it was the Refractory Anemia with Ringed Sideroblasts, (RARS) subtype.  I was ...

    Patient Chronicle last updated 05/10/2018 - 11:01am.

  4. Eltrombopag for the treatment of aplastic anemia: current perspectives

    ... patients. A significant proportion of patients are refractory to IST or relapse after IST. Various strategies have been ... as an encouraging and promising agent for patients with refractory AA. It has demonstrated efficacy in restoring trilineage ...

    Research Article last updated 11/01/2016 - 2:01pm.

  5. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. PATIENTS AND METHODS: ... non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Response to lenalidomide was ...

    Research Article last updated 07/18/2016 - 10:30am.

  6. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the Europ

    ... not achieve complete remission (CR) and 13% had primary refractory disease. On univariate analysis, outcomes at 3 years were not ... 32%), and fewer patients (10% versus 20%) with primary refractory disease in the CC group than in the HMA group (10% versus 19%, ...

    Research Article last updated 07/18/2016 - 11:22am.

  7. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

    ... restricted to select patients. New strategies for ESA- refractory or relapsed patients include lenalidomide , alone or in ...

    Research Article last updated 12/09/2016 - 2:50pm.

  8. Left main crossover stenting in a patient with severe thrombocytopenia due to aplastic anemia

    ... 11 × 103/μL, hemoglobin 6.4 g/dL). Refractory heart failure persisted despite repeated conservative ...

    Research Article last updated 12/09/2016 - 2:08pm.

  9. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts

    ... Mutations of SF3B1 occur in up to 90% of patients with refractory anaemia with unilineage dysplasia (RARS) and 70% of those with refractory cytopenia with multilineage dysplasia and ring sideroblasts ...

    Research Article last updated 08/15/2016 - 11:29am.

  10. A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

    ... World Health Organization (WHO) criteria (Appendix 2) or refractory anemia with excess blasts in transformation (RAEB t) ...

    Clinical Trial last updated 05/04/2018 - 3:53pm.